Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
Status:
Completed
Trial end date:
2019-06-03
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the clinical efficacy, safety and tolerability of
apremilast (30 mg twice daily [BID] and 40 mg BID), compared with placebo, in participants
with active Ulcerative Colitis (UC).